DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5745f3/ukireland_biotech) has announced the addition of the "UK/Ireland Biotechnology Sector: Clinical Phase Drug Development Pipeline" report to their offering.
This report identifies all UK and Irish biotechnology companies with drug candidates that have entered clinical trials. All clinical phase drug candidates being developed by these companies are listed, both by clinical trial phase and by the category of disease (ICD-10) that they are intended to address. A table is provided containing a brief outline of each company (public/private status, geographic location, web address, focus of activity, pipeline summary). This information is likely to be of use to, inter alia, parties contemplating licensing, merger or acquisition activity in the UK/Irish biotechnology sector, or parties intending to provide specific products or services to companies in this sector.
The precise scope of the report is constrained by the following definitions.
- Biotechnology companies' are defined as companies engaged in life sciences research and development with 2010 revenues of less than UKP 100 million (USD -160 million). Therefore, this report does not include big pharma' and other large organisations.
- UK and Irish biotechnology companies' means biotechnology companies with corporate headquarters in England, the Republic of Ireland, Northern Ireland, Scotland or Wales. Therefore, with one exception, this report does not include UK/Irish subsidiaries of foreign companies, even where the main R&D base is located in the UK.
- Drug candidates' means chemical or biological entities intended for the prevention or treatment of medical problems in humans. Therefore, the report does not include UK/Irish companies with activities limited to development of medical devices, diagnostics, veterinary products, research reagents or other research tools, biomedical software, or biopharmaceutical services (including contract clinical research, drug discovery, formulation, etc). The report excludes medical devices, but includes some drug-device combinations.
- Clinical phase' means any of Phase I - Phase IV clinical trials. The report does not include companies with only pre-clinical stage drug candidates, does not include companies with only approved drugs, does not identify the pre-clinical drug candidates of any companies, and does not identify the approved drugs of any companies.
Drug candidates which have been withdrawn from development due to poor safety or efficacy data are not knowingly included, but it cannot be guaranteed that all identified drug candidates are in active development.
Partnered programmes are not included in the pipeline of a given company where the programme involves use of the company's technology to modify (e.g. by reformulation) a drug candidate owned by a third party. In such instances, the drug candidate is listed only in the third party pipeline (if the third party is based in UK/Ireland).
In this report, clinical phase drug candidates are categorised by:
- clinical trial phase (I, II or =III); and
- international classification of disease (ICD-10) groupings.
For each of the 22 ICD-10 disease categories, a table is provided showing all UK/Irish clinical phase drug development activity in that category. Within each of these tables, drug development activity is presented by clinical trial phase, and the drug candidate and drug developer are identified. Brief clarifying notes are appended to many of the tables.
In addition, UK and Irish companies with clinical phase drug development programmes are categorised by:
- geographic location of corporate headquarters (England, Ireland including Northern Ireland, Scotland or Wales); and
- public or private status.
Finally, an index table is provided in which all UK and Irish companies with clinical phase drug development programmes are listed in alphabetical order, and in which each company is briefly outlined (public/private status, geographic location, web address, focus of activity, pipeline summary).
The above information is presented as 23 Tables and 7 charts.
For more information visit http://www.researchandmarkets.com/research/5745f3/ukireland_biotech